Navidea Biopharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig A. Dais
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4995 Bradenton Avenue Dublin OH United States of America 43017-3552
- IPO Date
- Nov 9, 1992
- CIK
- 0000810509
- Website
- navidea.com
- Similar Companies
- Business
- Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, leveraging its Manocept platform to identify sites and pathways of disease and enhance diagnostic accuracy, clinical decision-making, and targeted treatment. The company pursues multiple precision-targeted products based on the Manocept technology to address cancer, autoimmune conditions, and other inflammatory diseases, with Tc99m tilmanocept as its first commercially developed radiopharmaceutical product. Navidea operates in the United States and international markets through partnerships and distribution arrangements, and maintains a corporate presence in Dublin, Ohio, where it is headquartered. Founded in 1983, Navidea advances diagnostics and therapeutics through ongoing clinical development, strategic collaborations, and pipeline expansion across diagnostic radiopharmaceuticals, targeted imaging agents, and related immunotherapy approaches. Key product areas include diagnostic radiopharmaceuticals for lymph node mapping and disease visualization, as well as investigational therapeutic and imaging programs designed to enable earlier and more precise treatment decisions for patients with solid tumors, autoimmune diseases, and inflammatory conditions. The company’s product portfolio and research programs are complemented by collaboration efforts with strategic partners to advance its clinical programs toward regulatory submissions and potential commercial deployment. Navidea’s business model centers on leveraging its platform to improve detection of disease sites, enable better clinical decision-making, and support personalized treatment strategies in collaboration with healthcare providers and industry partners.
Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock
NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
Navidea Biopharmaceuticals rejects ProPhase Labs offer
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment